Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1298-1305

  De Rosa, Salvatore ^a   Caiazzo, Gianluca ^a   Torella, Daniele ^a   Indolfi, Ciro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Abciximab; Acute coronary syndrome; Intracoronary

Indexed keywords

ABCIXIMAB; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; DRUG DOSAGE FORM COMPARISON; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ABCIXIMAB; ACUTE CORONARY SYNDROME; INTRACORONARY;

ACUTE CORONARY SYNDROME; ANTIBODIES, MONOCLONAL; CORONARY VESSELS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84885319206     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.12.003     Document Type: Article

References (25)

1. McManus DD, Chinali M, Saczynski JS, et al. 30-year trends In heart failure In patients hospitalized with acute myocardial Infarction. Am J Cardiol 2011;107: 353-9.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial Infarction In patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.
3. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp Iib-iiia Inhibitors among patients with ST-segment elevation myocardial Infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009;30:2705-13.
4. Wöhrle J, Nusser T, Mayer C, Kochs M, Hombach V. Intracoronary application of abciximab In patients with ST-elevation myocardial Infarction. EuroIntervention 2008;3:465-9.
5. Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus Intravenous bolus abciximab during primary percutaneous coronary Intervention In patients with acute ST-elevation myocardial Infarction: a randomised trial. Lancet 2012;379:923-31.
6. Iversen AZ, Galatius S, Abildgaard U, et al. Intracoronary compared to Intravenous abciximab In patients with ST segment elevation myocardial Infarction treated with primary percutaneous coronary Intervention reduces mortality, target vessel revascularization and reinfarction after 1 year. Cardiology 2011;120:43-9.
7. Iversen A, Abildgaard U, Galloe A, et al. Intracoronary compared to Intravenous bolus abciximab during primary percutaneous coronary Intervention In ST-segment ElevationMyocardial Infarction (STEMi) patients reduces 30-daymortality and target vessel revascularization: a randomized trial. J Interv Cardiol 2011;24:105-11.
8. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with Intravenous bolus abciximab application In patients with ST-elevation myocardial Infarction undergoing primary percutaneous coronary Intervention: the randomized Leipzig Immediate percutaneous coronary Intervention abciximab IV versus IC In ST-elevation myocardial Infarction trial. Circulation 2008;118:49-57.
9. Eitel I, Friedenberger J, Fuernau G, et al. Intracoronary versus Intravenous bolus abciximab application In patients with ST-elevation myocardial Infarction undergoing primary percutaneous coronary Intervention: 6-month effects on Infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab I.v. versus I.c. In ST-Elevation Myocardial Infarction Trial (LiPSiAbciximab-STEMi). Clin Res Cardiol 2011;100:425-32.
10. Gu YL, KampingaMA,Wieringa WG, et al. Intracoronary versus Intravenous administration of abciximab In patients with ST-segment elevation myocardial Infarction undergoing primary percutaneous coronary Intervention with thrombus aspiration: the comparison of Intracoronary versus Intravenous abciximab administration during emergency Reperfusion of ST-segment elevation myocardial Infarction (CiCERO) trial. Circulation 2010;122:2709-17.
11. Bertrand OF, Rodés-Cabau J, Larose E, et al. Intracoronary compared to Intravenous Abciximab and high-dose bolus compared to standard dose In patients with ST-segment elevation myocardial Infarction undergoing transradial primary percutaneous coronary Intervention: a two-by-two factorial placebo-controlled randomized study. EArly Discharge after Transradial Stenting of CoronarY Arteries In Acute Myocardial Infarction (EASY-Mi) Study Investigators. Am J Cardiol 2010;105:1520-7.
12. Lee CH, Ngo HM, Sewianto A, et al. Comparison between fixed-dose, Intracoronary bolus-only versus standard weight-adjusted dose, Intravenous bolus and Infusion administration of abciximab In patients undergoing primary percutaneous coronary Intervention. Int J Cardiol 2010;145:355-7.
13. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of Intracoronary vs. Intravenous administration of abciximab In coronary stenting. Catheter Cardiovasc Interv 2004;61:31-4.
14. Wöhrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with Intracoronary compared with Intravenous bolus application of abciximab In patients with acute myocardial Infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107:1840-3.
15. Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ. Does Intracoronary abciximab Improve the outcome of percutaneous coronary Interventions? A randomized controlled trial. Rev Esp Cardiol 2006;59:567-74.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of Interventions. Oxford: The Cochrane Collaboration; 2008.
17. Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448-52.
18. DerSimonian R, Laird N. Meta-analysis In clinical trials. Control Clin Trials 1986;7: 177-88.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
20. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing Intracoronary versus Intravenous abciximab In patients with ST-elevation myocardial Infarction undergoing primary percutaneous coronary Intervention. Am J Cardiol 2012;109:624-8.
21. Schulz S, Birkmeier KA, Ndrepepa G. One-year clinical outcomes with abciximab In acute myocardial Infarction: results of the BRAVE-3 randomized trial. Clin Res Cardiol 2010;99:795-802.
22. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance Imaging In patients with acute myocardial Infarction. Circulation 1998;97:765-72.
23. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy In patients with large anterior myocardial Infarction: the INFUSE-AMi randomized trial. JAMA 2012;307:1817-26.
24. Desch S, Siegemund A, Scholz U, et al. Platelet Inhibition and GP Iib/iiia receptor occupancy by Intracoronary versus Intravenous bolus administration of abciximab In patients with ST elevation myocardial Infarction. Clin Res Cardiol 2012;101:117-24.
25. Bonello L, Pansieri M, Mancini J, et al. high on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary Intervention In acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73.